一项实用性、随机、开放标签、多中心英国注册辅助试验:评估高剂量胆钙化醇对透析患者死亡率的影响——SIMPLIFIED试验
SIMPLIFIED试验计划从英国72个肾脏中心招募成人透析患者,按1:1随机分配至高剂量开放标签胆钙化醇组或标准治疗组,主要终点为全因死亡率。预计约4200例患者、观察约2200例死亡、约7年随访,以90%把握度检出风险比0.87。
要点
- 透析患者维生素D缺乏常见且是心血管病、感染和癌症死亡的强预测因子。
- 现行指南推荐使用无活性维生素D3(胆钙化醇)替代活性维生素D化合物,但其对临床结局的影响尚未在足够把握度的试验中验证。
- SIMPLIFIED试验采用实用性设计,利用常规收集数据(ONS死亡、HES次要终点)评估高剂量胆钙化醇能否改善透析患者生存。
核心结论
- SIMPLIFIED试验旨在检验高剂量胆钙化醇补充能否改善透析患者的生存。
研究设计与样本
- 实用性、随机、开放标签、多中心英国注册辅助试验,从英国72个肾脏中心招募成人透析患者。
- 按1:1比例随机分配至高剂量开放标签胆钙化醇组或标准治疗组,按中心分层。
- 预计共需纳入约4200例患者,观察约2200例死亡,随访约7年,以90%把握度检出风险比0.87。
主要发现
- 目前英国仅68%的透析患者生存3年或以上。
- 维生素D缺乏在终末期肾病患者中常见,并且是心血管疾病、感染和癌症死亡的强预测因子。
关键数值与推荐
- 主要终点为全因死亡率。
- 关键次要终点包括无心血管事件、感染和癌症的生存,以及使用Eq5D工具测量的生活质量和成本效果指标。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vitamin D deficiency is common in patients with end stage kidney disease (ESKD) and is a strong predictor of death from cardiovascular disease, infections and cancer. Currently only 68% of patients in the UK survive 3 years or more on dialysis. Vitamin D replacement typically utilises activated (1α-hydroxylated) vitamin D compounds allowing for impaired renal activation. However, this approach increases blood calcium concentrations and may paradoxically accelerate vitamin D catabolism. Contemporary treatment guidelines recommend replacement with inactive (unhydroxylated) vitamin D3 (cholecalciferol), instead relying on autocrine and paracrine vitamin D activation in target tissues. However, the impact of this approach on clinical outcomes has not yet been tested in adequately powered trials. METHODS: The SIMPLIFIED (Survival Improvement with Cholecalciferol in Patients on Dialysis) trial will test whether supplementation with high-dose cholecalciferol improves survival. Adult dialysis patients will be recruited from one of 72 UK renal centres, by local clinicians and research nurses, and randomly assigned in a 1:1 ratio to high-dose open-label cholecalciferol or standard care, stratified by site. Trial outcomes will be captured using existing data sources including Office of National Statistics (ONS) for deaths and Hospital Episode Statistics (HES) for secondary endpoints. The primary endpoint of the trial is all-cause mortality. Key secondary endpoints include survival free from cardiovascular events, infections and cancers, and quality of life and cost-effectiveness measures utilising the Eq5D tool. Severe adverse event line listings will be generated from HES data for safety reporting. In this superiority trial, it is anticipated that approximately 4200 patients in total will need to be enrolled to observe 2200 deaths over a period of about 7 years, which will yield 90% power to demonstrate a hazard ratio of 0.87. DISCUSSION: Outcomes for patients on dialysis remain very poor. The pragmatic design of this study leveraging routinely collected data streamlines trial conduct, reducing burden on patients and local site study staff. Furthermore, since cholecalciferol is a low-cost and easy to administer intervention, evidence of benefit could be readily incorporated into dialysis care across healthcare systems globally. TRIAL REGISTRATION: EudraCT Number: 2015-005003-88; ISRCTN Number: 15087616 (registration date 30th December 2015) ( https://doi.org/10.1186/ISRCTN15087616 ). Recruitment commenced in March 2017.
引用
- Humphrey TJL, Caskey FJ, Wheeler DC, et al. A pragmatic, randomised, open-label, multi-centre UK registry-facilitated trial evaluating the effect of high-dose cholecalciferol on mortality in patients on dialysis: the SIMPLIFIED trial. Trials. 2025. PMID: 41094532. doi:10.1186/s13063-025-09134-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。